Adverse outcomes in patients with atrial fibrillation and peripheral arterial disease: A report from the EURObservational research programme pilot survey on atrial fibrillation

Europace

Volumn 19, Issue 9, 2017, Pages 1439-1448

  Proietti, Marco ^a   Raparelli, Valeria ^b   Laroche, Cécile ^c   Dan, Georghe Andrei ^d   Janion, Marianna ^e   Popescu, Raluca ^d   Sinagra, Gianfranco ^f   Vijgen, Johan ^g   Boriani, Giuseppe ^h,i   Maggioni, Aldo P ^c,j   Tavazzi, Luigi ^k   Lip, Gregory Y H ^a,l  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c European Society of Cardiology   (France)

^d CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^e JAN KOCHANOWSKI UNIVERSITY   (Poland)

^f UNIVERSITY OF TRIESTE   (Italy)

^g JESSA HOSPITAL   (Belgium)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^j ANMCO RESEARCH CENTER   (Italy)

^k MARIA CECILIA HOSPITAL   (Italy)

^l AALBORG UNIVERSITY   (Denmark)

more..

Author keywords

All cause death; Atherosclerosis; Atrial fibrillation; Peripheral arterial disease

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; CARDIOVASCULAR AGENT;

AGE; AGED; ALL CAUSE MORTALITY; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC KIDNEY FAILURE; CLINICAL FEATURE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HEALTH SURVEY; HEART FAILURE; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PILOT STUDY; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK FACTOR; SEX DIFFERENCE; THROMBOEMBOLISM; TRANSIENT ISCHEMIC ATTACK; CAUSE OF DEATH; CHI SQUARE DISTRIBUTION; CLINICAL TRIAL; COMPARATIVE STUDY; EUROPE; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; MULTIVARIATE ANALYSIS; ODDS RATIO; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; REGISTER; RISK ASSESSMENT; STATISTICAL MODEL; TIME FACTOR; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ATRIAL FIBRILLATION; CARDIOVASCULAR AGENTS; CAUSE OF DEATH; CHI-SQUARE DISTRIBUTION; EUROPE; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; ODDS RATIO; PERIPHERAL ARTERIAL DISEASE; PILOT PROJECTS; PREVALENCE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; REGISTRIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS;

EID: 85030549069     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/euw169     Document Type: Article

References (43)

1. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M et al. Heart disease and stroke statistics - 2015 update: a report from the American Heart Association. Circulation 2014;131:e29-322.
2. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res 2015; 116:1509-26.
3. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM et al. Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013;382: 1329-40.
4. Raparelli V, Proietti M, Napoleone L, Bucci T, Talerico G, Pignataro FS et al. Asymptomatic peripheral artery disease and antiplatelet management. Vasa 2014;43:309-25.
5. Aboyans V, Criqui MH, Abraham P, Allison MA, Creager MA, Diehm C et al. Measurement and interpretation of the Ankle-Brachial Index: a scientific statement from the American Heart Association. Circulation 2012;126:2890-909.
6. Goto S, Bhatt DL, Rö ther J, Alberts M, Hill MD, Ikeda Y et al. Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 2008;156:855-63, 863.e2.
7. Naccarelli GV, Varker H, Lin J, Schulman KL. Increasing prevalence of atrial fibrillation and flutter in the United States. Am J Cardiol 2009;104:1534-9.
8. Griffin WF, Salahuddin T, O'Neal WT, Soliman EZ. Peripheral arterial disease is associated with an increased risk of atrial fibrillation in the elderly. Europace 2016;18:794-8.
9. Anandasundaram B, Lane DA, Apostolakis S, Lip GYH. The impact of atherosclerotic vascular disease in predicting a stroke, thromboembolism and mortality in atrial fibrillation patients: a systematic review. J Thromb Haemost 2013;11:975-87.
10. Lip GYH, Nieuwlaat R, Pisters R, Lane DA, Crijns HJGM. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 2010;137:263-72.
11. Soliman EZ, Safford MM, Muntner P, Khodneva Y, Dawood FZ, Zakai NA et al. Atrial fibrillation and the risk of myocardial infarction. JAMA Intern Med 2014; 174:107-14.
12. Soliman EZ, Lopez F, O'Neal WT, Chen LY, Bengtson L, Zhang Z-M et al. Atrial fibrillation and risk of ST-segment-elevation versus non-ST-segment-elevation myocardial infarction: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2015;131:1843-50.
13. Violi F, Dav?G, Proietti M, Pastori D, Hiatt WR, Corazza GR et al. Ankle-Brachial Index and cardiovascular events in atrial fibrillation. The ARAPACIS Study. Thromb Haemost 2016;115:856-63.
14. Vermond Ra, Van Gelder IC, Crijns HJ, Rienstra M. Does myocardial infarction beget atrial fibrillation and atrial fibrillation beget myocardial infarction? Circulation 2015;131:1824-6.
15. Violi F, Lip GYH, Basili S. Peripheral artery disease and atrial fibrillation: a potentially dangerous combination. Intern Emerg Med 2012;7:213-8.
16. Violi F, Dav G, Hiatt W, Lip GYH, Corazza GR, Perticone F et al. Prevalence of peripheral artery disease by abnormal ankle-brachial index in atrial fibrillation: implications for risk and therapy. J Am Coll Cardiol 2013;62:2255-6.
17. Jones WS, Hellkamp AS, Halperin J, Piccini JP, Breithardt G, Singer DE et al. Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF. Eur Heart J 2014;35:242-9.
18. Lip GYH, Laroche C, Dan G-A, Santini M, Kalarus Z, Rasmussen LH et al. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry. Europace 2014; 16:308-19.
19. Lip GYH, Laroche C, Ioachim PM, Rasmussen LH, Vitali-Serdoz L, Petrescu L et al. Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry). Eur Heart J 2014;35: 3365-76.
20. Lip GYH, Skjøth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin, or no therapy in patients with nonvalvular AF with 0 or 1 stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015;65:1385-94.
21. Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Europace 2012;14:1385-413
22. Lip GYH, Frison L, Halperin JL, Lane DA. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drug. J Am Coll Cardiol 2011;57: 173-80.
23. Rasmussen LH, Larsen TB, Due KM, Tjønneland A, Overvad K, Lip GYH. Impact of vascular disease in predicting stroke and death in patients with atrial fibrillation: the Danish diet, cancer and health cohort study. J Thromb Haemost 2011;9:1301-7.
24. Chen LY, Roetker NS, Alonso A, Nazarian S, Polak J, Folsom AR et al. Carotid intima-media thickness, carotid distensibility, and incident atrial fibrillation: the Multi-Ethnic Study of Atherosclerosis (MESA). Eur Heart J 2013;34:P4067.
25. Proietti M, Calvieri C, Malatino L, Signorelli S, Corazza GR, Perticone F et al. Relationship between carotid intima-media thickness and non valvular atrial fibrillation type. Atherosclerosis 2015;238:350-5.
26. Soliman EZ, Lopez F, O'Neal WT, Chen LY, Bengtson L, Zhang Z-M et al. Atrial fibrillation and risk of ST-segment elevation versus non-ST segment elevation myocardial infarction: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2015;131:1843-50.
27. Chao T-F, Huang Y-C, Liu C-J, Chen S-J,Wang K-L, Lin Y-J et al. Acute myocardial infarction in patients with atrial fibrillation with a CHA2DS2-VASc score of 0 or 1: a nationwide cohort study. Heart Rhythm 2014;11:1941-7.
28. Winkel TA, Hoeks SE, Schouten O, Zeymer U, Limbourg T, Baumgartner I et al. Prognosis of atrial fibrillation in patients with symptomatic peripheral arterial disease: data from the Reduction of Atherothrombosis for Continued Health (REACH) Registry. Eur J Vasc Endovasc Surg 2010;40:9-16.
29. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by re. Eur Heart J 2012;33:1635-701.
30. Tendera M, Aboyans V, Bartelink M-L, Baumgartner I, Clément D, Collet J-P et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatm. Eur Heart J 2011;32:2851-906.
31. Bonaca MP, Creager MA. Pharmacological treatment and current management of peripheral artery disease. Circ Res 2015;116:1579-98.
32. Kumbhani DJ, Steg PG, Cannon CP, Eagle KA, Smith SC, Goto S et al. Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. Eur Heart J 2014;35:2864-72.
33. Aung PP, Maxwell HG, Jepson RG, Price JF, Leng GC. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007;4: CD000123.
34. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17-24.
35. Lane DA, Lip GYH. Treatment of hypertension in peripheral arterial disease. Cochrane database Syst Rev 2013;12:CD003075.
36. Mancia G, Facchetti R, Parati G, Zanchetti A. Visit-to-visit blood pressure variability, carotid atherosclerosis, and cardiovascular events in the European Lacidipine Study on Atherosclerosis. Circulation 2012;126:569-78.
37. Godfraind T. Calcium channel blockers in cardiovascular pharmacotherapy. J Cardiovasc Pharmacol Ther 2014;19:501-15.
38. Lichtlen PR, Hugenholtz PG, RafflenbeulW, Hecker H, Jost S, Deckers JW. Retardation of angiographic progression of coronary artery disease by nifedipine. Results of the International Nifedipine Trial on Antiatherosclerotic Therapy (INTACT). INTACT Group Investigators. Lancet (London, England) 1990;335:1109-13.
39. Sievers P, Uhlmann L, Korkmaz-Icö z S, Fastner C, Bea F, Blessing E et al. Combined treatment with olmesartan medoxomil and amlodipine besylate attenuates atherosclerotic lesion progression in a model of advanced atherosclerosis. Drug Des Devel Ther 2015;9:3935-42.
40. Zanchetti A, Bond MG, Hennig M, Neiss A, Mancia G, Dal Palù C et al. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: Principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. Circulation 2002;106:2422-7.
41. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
42. Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. J Am Med Assoc 2009;301:1909-19.
43. Basili S, Raparelli V, Vestri A, Di Tanna GL, Violi F. Comparison of efficacy of antiplatelet treatments for patients with claudication. A meta-analysis. Thromb Haemost 2010;103:766-73.